OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
- Conditions
- Pancreatic Cancer
- Registration Number
- NCT00040183
- Lead Sponsor
- OSI Pharmaceuticals
- Brief Summary
The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 569
Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas;cancer which is unresectable, locally advanced or metastatic.
Must have evidence of disease (clinical or radiological). Male or female, 18 years or older. Patients may have received prior radiation treatment for management of local disease providing that disease progression has been documented.
All toxicities have resolved, and the last fraction of radiation treatment was completed at least 4 weeks prior to randomization.
Patients may not have received prior chemotherapy, other then 5FU (+/- folic acid) or gemcitabine given concurrently with radiation treatment as a 'radiosensitiser.'
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (140)
Arizona Clinical Research Center
🇺🇸Tucson, Arizona, United States
Highlands Oncology Group
🇺🇸Springdale, Arkansas, United States
Alta Bates Comprehensive Cancer Center
🇺🇸Berkeley, California, United States
Loma Linda University Cancer Institute
🇺🇸Loma Linda, California, United States
Metropolitan Hematology/Oncology Medical Group, Inc.
🇺🇸Los Angeles, California, United States
UCLA Medical Center
🇺🇸Los Angeles, California, United States
Kaiser Permanente
🇺🇸San Diego, California, United States
DeQuattro Community Cancer Center
🇺🇸Manchester, Connecticut, United States
New Britain General Hospital
🇺🇸New Britain, Connecticut, United States
Eastern Connecticut Oncology
🇺🇸Norwich, Connecticut, United States
Scroll for more (130 remaining)Arizona Clinical Research Center🇺🇸Tucson, Arizona, United States